Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
The higher tirzepatide doses of 10 and 15 mg were noninferior compared to insulin glargine for the change in HbA1c (primary endpoint)
* Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced- calorie diet and increased physical activity
High cardiorespiratory fitness levels largely mitigate the increased risk of cardiovascular and all-cause mortality associated with obesity [10, 11]
Italy Spain Rest of Europe Asia Pacific China Japan India South Korea South-east Asia Rest of Asia Pacific Latin America Brazil Argentina Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of the Middle East and Africa Competitive Landscape The competitive landscape of the Liraglutide and Semaglutide market includes major players such as Bachem Holding AG, Novo Nordisk A/S, Eli Lilly and Company, HEC Pharma Co., Pfizer Inc., Boehringer Ingelheim International GmbH, Shenzhen JYMed Technology Co
Medication shipped to your door
